Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial
Open Access
- 17 December 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 31 (11) , 1887-1894
Abstract
The TEMPO 3:4 Trial results suggested that tolvaptan had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease (ADPKD) patients. However, the use of categorical ‘albuminuria events’ may have resulted in a loss of sensitivity to detect changes. The aim of this study is to investigate the effects of tolvaptan on albuminuria as a continuous variable. Post hoc analysis of a 3-year prospective, blinded randomized controlled trial, including 1375 ADPKD patients. Albuminuria was measured in a spot morning urine sample prior to tolvaptan dosing and expressed as albumin-to-creatinine ratio (ACR). Baseline median (interquartile range) ACR was 3.2 (1.7–7.1) mg/mmol. Of note, 47.9% of ADPKD patients had normal, 48.7% moderately increased and 3.4% severely increased ACR. Subjects with higher baseline ACR had higher blood pressure and total kidney volume (TKV) and lower estimated glomerular filtration rate (eGFR). During follow-up, higher baseline ACR was associated with more rapid eGFR loss (P < 0.0001 for trend), but not with rate of growth in TKV. During the 3-year trial, ACR rose in placebo- and decreased in tolvaptan-treated patients (+0.23 versus −0.40 mg/mmol). The difference ACR increased over time, reaching a maximum of 24% at Month 36 (P < 0.001). At that time only a minor difference in blood pressure was observed (mean arterial pressure −1.9 mmHg for tolvaptan). The decrease in ACR was similar in all subgroups investigated, and remained after withdrawal of study drug. The beneficial effect of tolvaptan on TKV growth and eGFR loss was stronger in patients with higher baseline ACR. In ADPKD, higher baseline albuminuria was associated with more eGFR loss. Tolvaptan decreased albuminuria compared with placebo, independent of blood pressure. Treatment efficacy of tolvaptan on changes in TKV and eGFR was more readily detected in patients with higher albuminuria.Keywords
This publication has 27 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohortsKidney International, 2011
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohortsKidney International, 2011
- Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney DiseaseKidney and Blood Pressure Research, 2011
- Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseNew England Journal of Medicine, 2010
- Early Renal Abnormalities in Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2010
- Lowering Blood Pressure Reduces Renal Events in Type 2 DiabetesJournal of the American Society of Nephrology, 2009
- Effects of Strict Blood Pressure Control by a Long-Acting Calcium Channel Blocker on Brain Natriuretic Peptide and Urinary Albumin Excretion Rate in Japanese Hypertensive PatientsHypertension Research, 2008
- A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney diseaseKidney International, 2005